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Abstract
Background Adults with pulmonary hypertension associ-
ated with congenital heart disease (PH-CHD) often have
residual shunts. Invasive interventions aim to optimise pul-
monary flow and prevent right ventricular failure. However,
eligibility for procedures strongly depends on the adaptation
potential of the pulmonary vasculature and right ventricle
to resultant circulatory changes. Current guidelines are not
sufficiently applicable to individual patients, who exhibit
great diversity and complexity in cardiac anomalies.
Methods and Results We present four complex adult PH-
CHD patients with impaired pulmonary flow, including de-
tailed graphics of the cardiopulmonary circulation. All
these patients had an ambiguous indication for shunt in-
tervention. Our local multidisciplinary Grown-Ups with
Congenital Heart Disease team reached consensus regard-
ing a patient-tailored invasive treatment strategy, adjacent
to relevant guidelines. Interventions improved pulmonary
haemodynamics and short-term clinical functioning in all
cases.
Conclusions Individual evaluation of disease characteristics
is mandatory for tailored interventional treatment in PH-
CHD patients, adjacent to relevant guidelines. Both strict
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registration of cases and multidisciplinary and multicentre
collaboration are essential in the quest for optimal therapy
in this patient population.
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Background
Improvements in medical treatment have changed outcomes
in congenital heart disease (CHD), with increasingly com-
plex CHD patients reaching adulthood [1–3]. This rise is
accompanied by an increase in the prevalence of CHD-
related comorbidities such as pulmonary hypertension [3,
4]. Pulmonary hypertension especially develops in CHD
patients with a persistent shunt between the systemic and
pulmonary circulation and is caused by right ventricular
(RV) volume and pressure overload, eventually resulting in
pulmonary vascular remodelling and increased pulmonary
vascular resistance (PVR) [5–7]. The aim of intervention in
patients with pulmonary hypertension associated with con-
genital heart disease (PH-CHD) is to optimise pulmonary
flow and prevent RV failure. Targeted therapy for pul-
monary hypertension consists of prostacyclins, endothelin
receptor antagonists and phosphodiesterase-5 inhibitors and
can improve functional status in PH-CHD patients [8–10].
Paradoxically, it is suggested that targeted therapy and the
consequential reduction in PVR can cause an increase in
pulmonary shunt flow and may result in progression of
pulmonary endothelial damage [5, 11]. An alternative ap-
proach is to alter shunt size through invasive correction of
the circulation, as for instance through closure of a ventric-
ular septum defect (VSD). The aim of such a procedure is
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Fig. 1 Cardiac circulation of case 1 before and after closure of the
Potts’ shunt, including catheterisation images
However, eligibility for interventions strongly depends on
the severity of the pulmonary hypertension and the ability
of the pulmonary vasculature and right ventricle to adapt to
resultant circulatory changes.
Current consensus regarding invasive circulatory
adjustments in adults with PH-CHD
Publications regarding shunt adjustments in PH-CHD pa-
tients are scarce and mostly limited to rather general con-
sensus guidelines [11, 12]. However, pre-interventional
assessment of eligibility for intervention is mandatory, as
shunt procedures contain a high risk of deteriorating RV
overload in severe pulmonary hypertension. An irreversibly
high PVR is generally considered a contraindication for
shunt closure when a predominantly left-to-right shunt ex-
ists at rest [2, 11, 13, 14]. This kind of shunt functions
as a safety communication between the left and right heart
through which systolic shunt reversal can occur during ex-
ercise, when systemic vascular resistance decreases in con-
trast to the fixed PVR. Closure of this type of shunt renders
a decrease in RV afterload at rest. However, if the PVR re-
mains high after closure, inability of shunt reversal during
exercise can increase RV afterload and lead to progressive
RV failure [5]. In general, a PVR below 6 Wood units
(WU) is thought to be feasible for shunt intervention. If the
PVR exceeds this value but is less than two-thirds of the
systemic resistance, intervention can still be considered. In
line with this, the effective left-right shunt ratio (Qp:Qs)
should be at least 1.5 in the case of a bidirectional shunt, as
this inversely relates to the ratio between systemic and pul-
monary vascular resistance [2, 13–15]. RV dilatation, dys-
function and pulmonary regurgitation are other indications
for intervention, although manifest RV failure inherently
increases procedural risk [13]. Furthermore, invasive cor-
rections remain controversial after PVR reduction has been
achieved using targeted therapy for pulmonary hyperten-
sion [16–19]. When pulmonary hypertension persists after
repair, the haemodynamic situation is comparable with id-
iopathic pulmonary arterial hypertension and the prognosis
is deemed poor [6].
Patients with PH-CHD exhibit great diversity and com-
plexity in anatomic anomalies. The above-mentioned cri-
teria illustrate that criteria to determine eligibility for in-
tervention can be contradictory in individual cases. The
current study states that refinement in individual disease
characteristics, adjacent to relevant guidelines, is neces-
sary to define appropriate treatment. To that purpose, we
present four PH-CHD patients with worsening RV over-
load and an ambiguous indication for intervention. Shunt
adjustments were performed by experts in the field after the
local Grown-Ups with Congenital Heart Disease (GUCH)




A woman, born with Fallot’s tetralogy, initially received
a Potts’ shunt to augment pulmonary flow and stimulate
pulmonary development. After childhood a total correc-
tion with closure of the Potts’ shunt and subsequently pul-
monary valve replacement was performed (Fig. 1). Dur-
ing follow-up her clinical condition slowly declined and
magnetic resonance imaging showed RV dilatation with
an increase in end-diastolic volume (EDV) from 132 to
169 ml in 4 years (upper normal value: 157 ml based on
sex, age and body surface area) [20]. Contrast-enhanced
computed tomography revealed recanalisation of the Potts’
shunt. At catheterisation a pulmonary arterial pressure
(PAP) of 120/40 mmHg was found with a left ventricu-
lar end-diastolic pressure of 12 mmHg. The PVR was
11.2 WU in the presence of a 1.7 l/min left-right shunt.
Systemic blood pressure was 190/85 mmHg. Coiling of the
shunt was technically unfeasible. Therefore, at the age of
49 years, two covered stents were implanted in the aorta
occluding the Potts’ shunt. After the procedure the PAP
decreased to 100/35 mmHg. Subsequently an endothelin
receptor antagonist was started resulting in a further de-
crease in PAP to 80/25 mmHg with a PVR of 5.5 WU. She
improved clinically and RV function remained reasonable
with a stable EDV of 165 ml. RV stroke volume increased
from 61 to 89 ml, tricuspid regurgitation decreased from
grade III to I and resting heart rate decreased from 91 to
68 bpm. Currently she remains clinically stable with more
than ten years of follow-up.
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Fig. 2 Cardiac circulation of case 2 before and after balloon atriosep-
tostomy
Case 2
This woman was born with pulmonary atresia, a large VSD
and major aortopulmonary collateral arteries (MAPCAs).
She underwent consecutive placement of bilateral modified
Blalock-Taussig shunts and ligation of MAPCAs. Subse-
quently a staged total correction, including fenestrated VSD
closure, tricuspid valve plasty, RV outflow tract reconstruc-
tion and pulmonary valve replacement was performed. Pul-
monary hypertension was diagnosed during follow-up and
an endothelin receptor antagonist was administered. She
developed progressive RV failure with multiple episodes
of decompensation. Heart transplantation was denied be-
cause of thoracic deformities. RV overload deteriorated
after a pulmonary infection, despite extensive diuretic and
inotropic treatment. Echocardiography showed severe hep-
atic vein dilatation and a large quantity of ascites. She was
23 years old and her short-term prognosis was deemed to
be very poor. It was decided to perform a balloon atriosep-
tostomy to relieve some RV overload by creating an ad-
ditional shunt (Fig. 2). After intervention she gradually
improved and the intravenous medication could be reduced.
Systemic flow increased from 3.0 to 4.9 l/min. Furthermore,
although systemic saturation dropped from 100 to 85 %, ar-
terial oxygen supply increased from 453 to 629 ml/min
through increased systemic flow. Unfortunately, four days
after the procedure she developed a fatal ventricular rhythm
disorder.
Case 3
A woman, born with Fallot’s tetralogy, pulmonary atresia
and a right-sided aortic arch, received bilateral Blalock-
Taussig shunts with ligation of MAPCAs. Subsequently the
Fig. 3 Cardiac circulation of case 3 before and after pulmonary artery
stenting and fenestrated VSD closure
RV outflow tract and pulmonary artery were reconstructed.
During follow-up she developed progressive pulmonary hy-
pertension resulting in a ventricular pressure equilibrium.
PAP was 110/15 mmHg in the presence of hypoplastic
pulmonary vasculature and in combination with severe
pulmonary regurgitation. The result was a predominantly
right-to-left VSD shunt and Eisenmenger physiology with
a haemoglobin level of 13.3 mmol/l. Stenoses in the left
and right pulmonary artery protected most of the peripheral
pulmonary vasculature from pressure overload. At the age
of 26 years the pulmonary vascular tree was corrected
in a hybrid surgical and percutaneous procedure through
pulmonary valve replacement and stenting of peripheral
pulmonary stenoses. In the same session the VSD was
reduced in size using a fenestrated patch (Fig. 3). After
the operation the PAP decreased to 85/40 mmHg. Through
pulmonary hypertension targeted therapy, the PAP dropped
further to 75/20 mmHg. The Qp:Qs rate increased from
0.60 to 1.12, haemoglobin level normalised to 9.5 mmol/l
and peripheral arterial saturation increased from 82 to 90 %,
all indicating a decline in de-oxygenated right-left shunt.
After 7 years of follow-up her clinical condition currently
remains stable.
Case 4
This woman was diagnosed with a double inlet left ven-
tricle, a rudimentary right ventricle, ventriculo-arterial dis-
cordance, a large VSD, patent ductus arteriosus and pul-
monary stenosis. A Blalock-Taussig shunt was placed at
adult age. During follow-up she developed progressive dys-
pnoea with exercise-induced peripheral desaturation and be-
came dependent on supplementary oxygen. Catheterisation
showed a PAP of 87/43 mmHg measured after the pul-
Neth Heart J (2016) 24:400–409 407
Fig. 4 Cardiac circulation of case 4 before and after graded balloon
atrioseptostomy
monary stenosis with a PVR of 6.9 WU. Mean left atrial
pressure was 20 mmHg in the presence of a significant
pulmonary venous atrioventricular valve stenosis. It was
hypothesised that the elevated pulmonary venous pressure
formed an important cause of her poor functional status.
Balloon dilatation of the atrioventricular valve was deemed
unfeasible, predominantly because of insufficient annulus
support. Therefore, at the age of 47 years, a graded balloon
atrioseptostomy was performed to create a restricted left-
right atrial shunt that would relieve pulmonary congestion,
improve pulmonary flow and thereby increase systemic sat-
uration (Fig. 4). Since the monoventricle distributed flow
over the pulmonary and systemic circulation inversely to
their respective afterloads, the atrioseptostomy was made
restrictive to prevent an excessive shunting volume and to
protect the monoventricle and pulmonary circulation from
flow overload. Left atrial pressure decreased from 20 to
14 mmHg after the procedure, while right atrial pressure
increased from 4 to 8 mmHg and systemic saturation in-
creased from 83 to 87 %. Pulmonary flow increased from
5.4 to 7.6 l/min and effective pulmonary flow (true flow of
deoxygenated blood) increased from 2.2 to 3.0 l/min. The
remaining pulmonary hypertension was treated with an en-
dothelin receptor antagonist. After intervention, unchanged
diuretic treatment resulted in re-compensation and clinical
improvement with an increase in six-minute walking dis-
tance from 179 metres before intervention to 336 metres
3 months post procedure. The created atrial septal defect
turned out to decrease in size during follow-up and there-
fore the procedure was repeated twice more. Unfortunately,
two years after the first atrioseptostomy she developed se-
vere progressive heart failure with serious comorbidities
and died after a hip fracture.
Discussion
This study presents four patients with complex CHD-PH,
impaired pulmonary flow and progressive ventricular over-
load. All these patients had an ambiguous indication for
shunt adjustment according to the current guidelines. In
the first patient with corrected Fallot’s tetralogy and re-
canalisation of a Potts’ shunt, RV dilatation formed a class
IB indication for intervention. On the contrary, the high
PVR formed a strong contraindication and the remaining
pulmonary hypertension would be associated with poor out-
come [2, 13]. However, in this patient the combined ther-
apy of shunt closure and targeted therapy for pulmonary
hypertension resulted in enhancement of RV function and
long-term clinical improvement. The second patient with
chronic right heart overload underwent an atrioseptostomy
to increase systemic cardiac output. Guidelines do not com-
ment on atrioseptostomy in the case of RV overload in PH-
CHD. However, this procedure is described in other types of
pulmonary arterial hypertension with acceptable results [21,
22]. The procedure resulted in enhanced systemic oxygen
delivery and short-term clinical improvement. However, it
cannot be excluded that the decreased peripheral satura-
tion contributed to the fatal arrhythmia. In the third patient
with surgically palliated extreme Fallot’s tetralogy, the pre-
dominantly right-left shunt and severe pulmonary hyperten-
sion formed strong contraindications for VSD closure [2,
13]. Fenestrated VSD closure reduced shunt volume, while
maintaining a safety communication between the two ven-
tricles [23]. In combination with pulmonary artery stenting
and medical therapy a reduction in PAP and increase in
pulmonary flow was achieved, resulting in enhanced sys-
temic oxygen supply, normalisation of haemoglobin level
and long-term clinical improvement. The last patient had
a functional monoventricle with severe stenosis of the pul-
monary venous atrioventricular valve for which a graded
atrioseptostomy was performed. The literature states that
intervention is indicated when symptomatic pulmonary ve-
nous obstruction is present [2]. However, the delicate equi-
librium in this monoventricular circulation with combined
arterial and venous pulmonary hypertension formed a high
risk of cardiac deterioration if pulmonary overflow devel-
oped after intervention. Creation of a restrictive atrial shunt
prevented an excessive increase in flow to the monoventri-
cle and pulmonary circulation and resulted in improvement
in pulmonary flow and clinical status.
In all cases the guidelines were inconclusive regarding
eligibility for intervention. However, all these patients ex-
perienced progressive ventricular overload with diminished
prognosis if left untreated. The local GUCH team reached
consensus regarding a tailored invasive treatment strategy
based on expert opinion adjacent to relevant guidelines. In
these patients, intervention improved pulmonary flow and
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Fig. 5 Diversity in possible targets for invasive intervention in PH-CHD patients to optimise pulmonary flow and prevent RV failure, with the
presented patients depicted by case numbers
clinical functioning. Currently, the guidelines are not ex-
tended enough to cover the wide pathophysiological spec-
trum of PH-CHD in the assessment of eligibility for in-
tervention. Fig. 5 gives an overview of the diversity in
possible targets for intervention in PH-CHD patients to op-
timise pulmonary flow and prevent RV failure, with the pre-
sented patients depicted by case numbers. This overview
illustrates the wide variety in cardiac anomalies in this pop-
ulation as well as the different mechanisms that impaired
pulmonary flow and were taken into account to determine
treatment strategy in the presented cases. The current rise
in adult patients with complex CHD-PH makes the debate
about intervention increasingly relevant. In the past, sim-
ilar case reports have been published concerning invasive
interventions in patients with pulmonary hypertension and
various forms of CHD, which contribute to the statement
that tailored interventions can improve clinical status when
guidelines are inconclusive [24, 25]. More publications of
individual experiences are warranted to further enhance in-
sight into outcomes after intervention. Moreover, prospec-
tive documentation of cases in preferably large registries is
necessary to increase knowledge about the clinical course
of this population and the effect of treatment strategies. Es-
pecially in the field of GUCH, such registries have proven
to be very useful for evaluation of outcome and best prac-
tice [26, 27]. At present, we conclude that improvement in
pulmonary flow and clinical functioning can be achieved in
selected patients with complex CHD-PH through combina-
tion of tailored invasive and medical treatment.
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